SCHEMBL1648596

SCHEMBL1648596

c1ccc2c(c1)NCNS2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.45
ALDH1A1 P00352 6/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
MAPT P10636 4/20 0.39
POLB P06746 2/20 0.39
ALOX12 P18054 2/20 0.39
NOX1 Q9Y5S8 2/20 0.39
ALOX15 P16050 2/20 0.39
CYP1A2 P05177 1/20 0.39
BCHE P06276 1/20 0.39
CYP3A4 P08684 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
MAOA P21397 1/20 0.39
CNR1 P21554 1/20 0.39
ACHE P22303 1/20 0.39
PTGS1 P23219 1/20 0.39
SLC6A2 P23975 1/20 0.39
HTR2C P28335 1/20 0.39
PTGS2 P35354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4642441 0.80 GAA (0.53) GAAALDH1A1MEN1KMT2AMAPT
SCHEMBL28812738 0.79 DYRK2 (0.35) GAAALDH1A1MEN1KMT2ATDP1
SCHEMBL6140694 0.71 NOX1 (0.41) GAAMEN1KMT2AMAPTNOX1
SCHEMBL30876858 0.71 NOX1 (0.41) GAAMEN1KMT2AMAPTNOX1
SCHEMBL27826779 0.71 RPS6KA3 (0.35) MAPTNOX1BCHEACHEHTR2C
SCHEMBL4488749 0.70 GAA (0.52) GAAALDH1A1MEN1KMT2AMAPT
SCHEMBL30549 0.68
Hydrochloric Acid SCHEMBL31003509 0.66 GAA (0.41) GAAALDH1A1MEN1KMT2AMAPT
SCHEMBL10670210 0.66 ALOX15 (0.39) GAAALDH1A1MEN1KMT2AMAPT
SCHEMBL29452948 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 US disclosed
EP-3759092-A1 COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION University College Cardiff Consultants Ltd (GB) 2021-01-06 EP disclosed
WO-2018146486-A1 AMPA RECEPTOR POTENTIATORS THE UNIVERSITY OF SUSSEX (GB) 2018-08-16 WO disclosed
CN-102600171-A Structure utilizing benzothiadiazine and pyrazolothiadiazine derivatives as aldose reductase inhibitor, synthetic method and application BEIJING INST TECHNOLOGY 2012-07-25 CN disclosed
US-7927613-B2 Pharmaceutical co-crystal compositions UNIVERSITY OF SOUTH FLORIDA (US) 2011-04-19 US disclosed
EP-1026950-A1 TREATMENT OF SCHIZOPHRENIA WITH AMPAKINES AND NEUROLEPTICS CORTEX PHARMACEUTICALS, INC. (US) 2000-08-16 EP disclosed
WO-1999021422-A1 TREATMENT OF SCHIZOPHRENIA WITH AMPAKINES AND NEUROLEPTICS CORTEX PHARMACEUTICALS, INC. (US) 1999-05-06 WO disclosed
WO-1998012185-A1 BENZOTHIADIAZIDE DERIVATIVES AND THEIR USE AS ALLOSTERIC UP-MODULATORS OF THE AMPA RECEPTOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-03-26 WO disclosed
EP-0636124-A1 3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE-3-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME Aventis Pharma S.A. (FR) 1995-02-01 EP disclosed
WO-1993021170-A1 3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE-3-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME RHONE-POULENC RORER S.A. (FR) 1993-10-28 WO disclosed